Epidemiology and clinical features of emergency department patients with suspected COVID-19: Insights from Australia's 'second wave' (COVED-4)

AUTHOR(S)

Gerard O'Reilly, R D Mitchell, B Mitra, Hamed Akhlaghi, V Tran, Jeremy Furyk, P Buntine, A Wong, V Gangathimmaiah, Jonathan Knott, M Raos, E Chatterton, C Sevior, S Parker, S Baker, A Loughman, N Lowry, D Freeman, M Sri-Ganeshan, N Chapman, S Siu, M P Noonan, D V Smit, Peter A Cameron

ORIGINAL RESEARCH

Epidemiology and clinical features of emergency department patients with suspected COVID-19: Insights from Australia's 'second wave' (COVED-4)

Gerard M O'REILLY [1,2,3] Robert D MITCHELL [1,2] Biswadev MITRA [1,2,3] Hamed AKHLAGHI [4,5] Viet TRAN [6,7,8] Jeremy S FURYK [9,10] Paul BUNTINE,[11,12] Anselm WONG [13,14,15] Vinay GANGATHIMMAIAH,[16] Jonathan KNOTT [14,17] Max RAOS,[18] Erica CHATTERTON,[1,19,20] Carolyne SEVIOR,[1] Sophie PARKER,[1,21] Samuel BAKER,[4] Ashley LOUGHMAN,[6,22] Nicole LOWRY,[9] Dylan FREEMAN,[11] Muhuntha SRI-GANESHAN,[13] Nicole CHAPMAN,[16] Sherman SIU,[18] Michael P NOONAN,[1,3,23] De Villiers SMIT[1,2,3] and Peter A CAMERON [1,2] on behalf of the COVED Project Team

[1]Emergency and Trauma Centre, Alfred Health, Melbourne, Victoria, Australia, [2]School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia, [3]National Trauma Research Institute, Alfred Health, Melbourne, Victoria, Australia, [4]Emergency Department, St Vincent's Hospital, Melbourne, Victoria, Australia, [5]Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia, [6]Emergency Department, Royal Hobart Hospital, Hobart, Tasmania, Australia, [7]Tasmanian School of Medicine, University of Tasmania, Hobart, Tasmania, Australia, [8]Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia, [9]Emergency Department, Barwon Health, Geelong, Victoria, Australia, [10]School of Medicine, Deakin University, Geelong, Victoria, Australia, [11]Emergency Department, Eastern Health, Melbourne, Victoria, Australia, [12]Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia, [13]Emergency Department, Austin Hospital, Melbourne, Victoria, Australia, [14]Department of Critical Care, The University of Melbourne, Melbourne, Victoria, Australia, [15]School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, [16]Emergency Department, Townsville University Hospital, Townsville, Queensland, Australia, [17]Emergency Department, The Royal Melbourne Hospital, Melbourne, Victoria, Australia, [18]Emergency Department, Sutherland Hospital, Sydney, New South Wales, Australia, [19]School of Nursing and Midwifery, La Trobe University, Melbourne, Victoria, Australia, [20]School of Nursing and Midwifery, Deakin University, Melbourne, Victoria, Australia, [21]Department of Anaesthetics, Peter MacCallum Hospital, Melbourne, Victoria, Australia, [22]Ambulance Tasmania, Hobart, Tasmania, Australia, and [23]Trauma Service, Alfred Health, Melbourne, Victoria, Australia

Abstract

Objective: The aim of the present study was to describe the epidemiology and clinical features of patients presenting to the ED with suspected and confirmed COVID-19 during Australia's 'second wave'.

Methods: The COVID-19 ED (COVED) Project is an ongoing prospective cohort study in Australian EDs. This analysis presents data from 12 sites across four Australian states for the period from 1 July to 31 August 2020. All adult patients who met the criteria for 'suspected COVID-19' and underwent testing for SARS-CoV-2 in the ED were eligible for inclusion. Study outcomes included a positive SARS-

Correspondence: Associate Professor Gerard M O'Reilly, Emergency and Trauma Centre, Alfred Health, 55 Commercial Road, Melbourne, VIC 3004, Australia, Email: gerard.oreilly@monash.edu

Gerard M O'Reilly, MBBS, MPH, MBiostat, AStat, PhD, FACEM, Emergency Physician, Adjunct Clinical Associate Professor, Head of Epidemiology and Biostatistics, NHMRC Research Fellow; Robert D Mitchell, MBBS (Hons), BMedSc (Hons), MPH&TM, GradCertDisRefHlth, FACEM, Emergency Physician, PhD Scholar; Biswadev Mitra, MBBS, MHSM, PhD, FACEM, Director of Emergency Medicine Research, Professor, Head of Clinical Research; Hamed Akhlaghi, MD, PhD, FACEM, GradDipClinUSS, Director of Emergency Medicine Research, Senior Lecturer; Viet Tran, MBBS, FACEM, Director of Emergency Medicine Research, Senior Lecturer, Senior Researcher; Jeremy S Furyk, MBBS, MPH&TM, MSc, PhD, FACEM, Emergency Physician, Senior Lecturer; Paul Buntine, MBBS (Hons), FACEM, Director of Emergency Medicine Research, Adjunct Senior Lecturer; Anselm Wong, MBBS, DipTox, PhD, FACMT, FAACT, FACEM, Emergency Physician, Clinical Toxicologist, Adjunct Clinical Associate Professor, NHMRC Research Fellow; Vinay Gangathimmaiah, MBBS, MPH, FACEM, Director of Emergency Medicine Research; Jonathan Knott, MBBS, MClinEd, PhD, FACEM, Associate Professor, Director of Emergency Research; Max Raos, MBChB, FACEM, Emergency Physician; Erica Chatterton, BN, GradCertAcCare, GradCertEmergCare, Emergency Nurse, Lecturer; Carolyne Sevior, BN, GradCertNurs (Emerg), Emergency Nurse; Sophie Parker, MBBS, FACEM, FRCEM, FCICM, Emergency Physician, High Acuity Consultant;

Key findings

- In this prospective multi-site study during Australia's 'second wave', a substantial proportion of ED patients required SARS-CoV-2 testing and isolation.
- Presence of SARS-CoV-2 on nasopharyngeal swab was associated with an increase in the odds of death and mechanical ventilation in hospital.

CoV-2 test result, mechanical ventilation and in-hospital mortality.

Results: There were 106 136 presentations to the participating EDs and 12 055 (11.4%; 95% confidence interval [CI] 11.2–11.6) underwent testing for SARS-CoV-2. Of these, 255 (2%) patients returned a positive result. Among positive cases, 13 (5%) received mechanical ventilation during their hospital admission compared to 122 (2%) of the SARS-CoV-2 negative patients (odds ratio 2.7; 95% CI 1.5–4.9, *P* = 0.001). Nineteen (7%) SARS-CoV-2 positive patients died in hospital compared to 212 (3%) of the SARS-CoV-2 negative patients (odds ratio 2.3; 95% CI 1.4–3.7, *P* = 0.001). Strong clinical predictors of the SARS-CoV-2 test result included self-reported fever, sore throat, bilateral infiltrates on chest X-ray, and absence of a leucocytosis on first ED blood tests ($P < 0.05$).

Conclusions: In this prospective multi-site study during Australia's 'second wave', a substantial proportion of ED presentations required SARS-CoV-2 testing and isolation. Presence of SARS-CoV-2 on nasopharyngeal swab was associated with an increase in the odds of death and mechanical ventilation in hospital.

Key words: *COVID-19, emergency, isolation, quality improvement, registry.*

Introduction

Health systems across the world continue to be impacted by the COVID-19 pandemic. While Australia has been relatively successful at containing the virus, a 'second wave' of infections in mid-2020 has demonstrated the need for vigilance. As of 22 November 2020, 27 892 cases and 907 deaths have been reported nationally, with an overall admission rate of approximately 13%.[1]

Despite the significant decline in community transmission,[1] a substantial proportion of Australian ED patients continue to meet criteria for 'suspected COVID-19' and therefore require isolation and testing.[2] This has led to a number of issues for EDs, particularly in terms of maintaining 'business as usual' in parallel with rigorous infection prevention and control (IPC) for suspected and confirmed cases.[3] As ED presentations and hospital occupancy return to baseline (following substantial reductions during the 'first wave'),[4,5] meeting these challenges has become increasingly complex.[6,7]

In this context, it is important that clinicians have access to contemporary data and evidence-based tools to guide clinical decisions and systems reform. In particular, there is a need for robust models that support timely risk-assessment and diagnosis.[2,8] Although the characteristics of hospitalised patients with confirmed COVID-19 are well described, relatively little has been published about the epidemiology, clinical features and outcomes of ED patients who undergo testing for SARS-CoV-2.[2,9–14] Additionally, no diagnostic and prognostic tools have been specifically developed, or validated, for the Australian ED context.[15]

The COVID-19 ED (COVED) Quality Improvement Project was initiated in response to these challenges.[16] COVED-1 and COVED-2, which coincided with Australia's 'first wave', demonstrated a low positive test rate, with no SARS-CoV-2 positive patients receiving mechanical ventilation or dying in the ED of the single participating site. These studies also identified a high number of patients meeting case definition criteria and requiring isolation.[17,18] COVED-3 reported data across eight EDs during July 2020, and revealed no difference in the rates of mechanical ventilation and in-hospital death between SARS-CoV-2 positive and negative patients. The main clinical predictors of a COVID-19 diagnosis were subjective fever, bilateral infiltrates on chest X-ray (CXR), non-smoking status and absence of leucocytosis.[2]

The present study (COVED-4) builds on the findings of COVED-3 with a broader sample of patients.[2] It reports data from 12 EDs, distributed across four states in eastern Australia, for July and August 2020. The study aimed to further explore the association between the SARS-CoV-2 test result in the ED and mechanical ventilation and in-hospital mortality, and to identify the clinical and epidemiological variables predictive of a COVID-19 diagnosis.

Methods

COVED is an ongoing prospective cohort study that commenced on 1 April 2020. The study protocol has been published previously.[16] The study includes adult patients who had a SARS-CoV-2 polymerase chain reaction (PCR) test requested in the ED and were managed with IPC precautions for 'suspected COVID-19'. Testing criteria are guided by the various health jurisdictions and have evolved throughout the Project.[19–22] The criteria that were applicable during the present study period are listed in Box 1. Patients who underwent testing for surveillance purposes (i.e. patients who were tested for SAR-CoV-2 in the ED but were not subjected to IPC precautions) were excluded.

This analysis (COVED-4) describes study findings for eligible patients who presented to the 12 participating EDs (The Alfred Hospital, St Vincent's Hospital Melbourne, Austin Hospital, Box Hill Hospital, The Royal

Samuel Baker, MBBS, Medical Officer; Ashley Loughman, MBBS, FACEM, Emergency Physician, Retrieval Consultant; Nicole Lowry, BN (Hons), GradDipNurs (Emerg), MAdvNursPrac (NP), Emergency Department Research Assistant; Dylan Freeman, MD, BSc (Adv), Medical Officer; Muhuntha Sri-Ganeshan, MBBS, BSc, DTMH, Medical Officer; Nicole Chapman, BN, MEmergN, Emergency Nurse; Sherman Siu, MD, Medical Officer; Michael P Noonan, MBChB (Hons), BPhty (Hons), MMEd, FACEM, Emergency Physician, Honorary Consultant, Trauma Consultant; De Villiers Smit, MBChB, FACEM, Emergency Physician, Director, Adjunct Associate Professor, Head of Emergency Medicine Program; Peter A Cameron, MBBS, MD, FACEM, Emergency Physician, Adjunct Professor.

BOX 1. *Summary of SARS-CoV-2 testing criteria during July and August 2020*

Victoria[19]

Any patient meeting the following criteria:

Fever OR chills in the absence of an alternative diagnosis that explains the clinical presentation

OR

Acute respiratory infection (e.g. cough, sore throat, shortness of breath, runny nose, loss or change in sense of smell or taste).

OR

Onset of other clinical symptoms associated with COVID-19) (e.g. headache, myalgia, stuffy nose, nausea, vomiting, diarrhoea) AND any of the following epidemiological criteria:

- Close contacts of a confirmed case of coronavirus (COVID-19)
- Returned overseas travel in the past 14 days
- Health care or aged care workers

OR

Unable to complete adequate patient history to exclude all listed criteria (e.g. altered conscious state)

OR

Presenting from residential aged care facility (August 2020).

Additionally, testing should be considered in older people, who may present with other atypical symptoms including functional decline, delirium, exacerbation of underlying chronic condition, falls, loss of appetite, malaise, nausea, diarrhoea and myalgia (August 2020).

Notes:

These criteria underwent minor changes throughout the study period. Further information is available on the Department of Health and Human Services website.[19]

Patients meeting the testing criteria in St Vincent's Hospital ED during July 2020 were included in this analysis if they were triaged to the designated primary suspected COVID-19 area in ED.

New South Wales[21]

Any patient with respiratory symptoms (cough, sore throat, shortness of breath, runny nose), loss of sense of smell or taste, or unexplained fever.

Queensland[22]

Any patient meeting essential (clinical and epidemiological) OR enhanced (only clinical) testing criteria.

Clinical criteria: fever (≥37.5°C) OR history of fever OR acute respiratory illness (rhinorrhoea/cough/sore throat/shortness of breath) OR acute fatigue/myalgia/arthralgia OR loss of smell/taste.

Epidemiological criteria: close contact of a confirmed case of COVID-19 OR international, interstate or cruise travel in the past 14 days OR health, aged or residential care worker with patient contact OR travelled through hotspot(s) OR admitted hospital patients with no other cause for their infection evident.

Tasmania[20]

Any patient with the following symptoms at any point in the last 7 days: fever or history of fever (e.g. night sweats, chills), rhinorrhoea, cough, sore throat, shortness of breath or loss of smell or taste.

Melbourne Hospital, University Hospital Geelong, Royal Hobart Hospital, Launceston General Hospital, North-West Regional Hospital, Mersey Community Hospital, Sutherland Hospital Sydney and Townsville University Hospital) over the period 1 July to 31 August 2020. These sites represent a mixture of urban and regional EDs across Victoria, Tasmania, New South Wales and Queensland (Table 1). In all of these locations, alternative non-ED testing sites (e.g. screening clinics) were in operation for those with minor symptoms who did not require ED care. These patients were not included in the present study.

COVED outcome measures include SARS-CoV-2 PCR test result, mechanical ventilation and hospital discharge destination. The complete list of variables has previously been published in the study protocol.[2,16] These include history (age, sex, symptoms, epidemiological features, co-morbidities), findings on clinical examination, radiological and blood investigations, care provided in the ED and hospital (including ED disposition destination) and patient outcomes (including survival to hospital discharge).[2] COVED variables and definitions have been harmonised with international COVID-19 research tools developed by the World Health Organization and International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC).[23]

The data for study participants are collected from the hospital electronic medical record systems. Some variables are automatically extracted from data warehouses; other variables require manual record review.[2] Data are entered into the COVED registry utilising Research Electronic Data Capture (REDCap) tools, hosted and managed by Helix (Monash University).[24,25] The data dictionary and case report form are available on The Alfred Hospital's academic programmes website at https://emergencyeducation.org.au/research/coved/.[2]

Summary descriptive statistics have been determined for each pre-specified variable; these data have been stratified by the test result for

TABLE 1. *Submitted cases for analysis and report by site*

Site	Total number of ED presentations†	Total adult cases tested for SARS-CoV-2, *n* (%)‡	SARS-CoV-2 positive, *n* (%)	SARS-CoV-2 negative, *n* (%)	Case data included in Tables 2 and 3	Case data included in Table 4
The Alfred Hospital	8481	2396 (28)	41 (2)	2355 (98)	All	All
Austin Hospital	11 796	1481 (13)	29 (2)	1452 (98)	SARS-CoV-2 positive	SARS-CoV-2 positive
Box Hill Hospital	8803	937 (11)	20 (2)	917 (98)	All	SARS-CoV-2 positive
Launceston General Hospital	7224	237 (3)	0 (0)	237 (100)	All	SARS-CoV-2 positive§
Mersey Community Hospital	3037	53 (2)	0 (0)	53 (100)	All	SARS-CoV-2 positive§
North West Regional Hospital	4601	66 (1)	0 (0)	66 (100)	All	SARS-CoV-2 positive§
Royal Hobart Hospital	10 978	354 (3)	1 (0)	353 (100)	All	SARS-CoV-2 positive
The Royal Melbourne Hospital	10 590	3436 (32)	93 (3)	3343 (97)	SARS-CoV-2 positive	Not included
St Vincent's Hospital Melbourne	6255	961 (15)¶	61 (6)¶	900 (94)¶	July: All¶ August: SARS-CoV-2 positive	July: All¶ August: SARS-CoV-2 positive
Sutherland Hospital	9243	579 (6)	0 (0)	579 (100)	All	SARS-CoV-2 positive§
Townsville University Hospital	14 643	1111 (8)	0 (0)	1111 (100)	All	SARS-CoV-2 positive§
University Hospital Geelong	10 485	444 (4)	10 (2)	434 (98)	All	SARS-CoV-2 positive
Total	106 136	12 055 (11)	255 (2)	11 800 (98)	6519	2676

†All ages. ‡Testing criteria as per Box 1. §No SARS-CoV-2 positive cases in study period. ¶Only including patients triaged to designated suspected COVID-19 area in ED (i.e. not whole ED) in July 2020.

the SARS-CoV-2 PCR swab taken in the ED. As for COVED-3,[2] there were sufficient SARS-CoV-2 positive cases to undertake inferential analyses (comparing predictors and outcomes by SARS-CoV-2 test result, with summary measures of association and 95% confidence intervals [CIs]). Symmetrical numerical data have been summarised using the mean and standard deviation; skewed and ordinal data have been summarised using the median and interquartile range; and categorical data have been summarised using the frequency and percentage.

The final prediction model was derived to avoid overfitting. Specifically the maximum number of clinical predictor variables included in the final (parsimonious) model was limited by the 'rule of thumb' whereby at least 10 observations of each outcome (SARS-CoV-2 positive and negative) are required per predictor variable.[2] Data were analysed using Stata statistical software (version 15.1; StataCorp, College Station, TX, USA). A *P*-value of <0.05 was defined to be statistically significant. Ethics approval was obtained from the Alfred Human Research Ethics Committee (Project No: 188/20) on 26 March 2020 and approved as a multi-site project (63444) on 9 April 2020.

The requirement for patient consent was waived.

Results

There were 106 136 ED presentations during the study period, and 12 055 (11.4%; 95% CI 11.2–11.6) met inclusion criteria. Of these, 255 (2%) patients returned a positive SARS-CoV-2 test result and 11 800 (98%) were negative (Table 1).

Table 2 summarises the baseline demographic and ED arrival characteristics of included patients. There were no differences in age or sex distribution. Patients who tested

TABLE 2. *Baseline demographic and ED arrival details by SARS-CoV-2 result from ED polymerase chain reaction*

Variable	SARS-CoV-2 positive, n (%) (n = 255)	SARS-CoV-2 negative, n (%) (n = 6264)	OR (95% CI)	P-value
Age in years, mean (SD)	58 (22)	58 (22)	1.0 (1.0–1.0)	0.85
Sex, n (%)				
Male	130 (51)	3054 (49)	1.1 (0.9–1.4)	0.49
Mode of transport, n (%)				
Private transport/other	60 (24)	1544 (41)	Reference group	
Ambulance – road	189 (73)	3501 (56)	2.6 (1.7–3.0)	<0.001
Ambulance – helicopter	0 (0)	37 (1)	—	—
Public transport	8 (3)	174 (3)	1.9 (0.9–4.1)	0.08
Triage category, median (IQR)	3 (2,3)	3 (2,3)	NA	0.40
Triage category, n (%)				
1	6 (2)	139 (2)	Reference group	
2	58 (23)	1464 (23)	0.9 (0.4–2.2)	0.85
3	142 (56)	3216 (51)	1.0 (0.4–2.4)	0.96
4	48 (19)	1276 (20)	0.9 (0.4–2.1)	0.76
5	1 (0)	160 (3)	0.1 (0.0–1.2)	0.08

—, category omitted from estimation because of perfect prediction (empty cell) or collinearity; CI, confidence interval; IQR, interquartile range; NA, not applicable; OR, odds ratio; SD, standard deviation.

positive for SARS-CoV-2 were more likely to have arrived by ambulance ($P < 0.001$), but there were no differences in assigned triage category.

Patient outcomes are summarised in Table 3. Of the SARS-CoV-2 positive patients, 19 (7%) died in hospital compared to 212 (3%) of the SARS-CoV-2 negative patients (odds ratio [OR] 2.3; 95% CI 1.4–3.7, $P = 0.001$). Thirteen (5%) of the SARS-CoV-2 positive patients received invasive mechanical ventilation during their hospital admission, compared to 122 (2%) of the SARS-CoV-2 negative patients (OR 2.7; 95% CI 1.5–4.9, $P = 0.001$). SARS-CoV-2 positive patients were more likely to be admitted to the intensive care unit (ICU) (OR 5.0; 95% CI 2.7–9.1, $P < 0.001$) or the general ward (OR 2.8; 95% CI 2.0–3.9, $P < 0.001$) than SARS-CoV-2 negative patients respectively.

Table 4 describes the clinical and epidemiological features of the sample (based on the available data from contributing sites, as summarised in Table 1). Cough (61%), fatigue (58%) and subjective fever (55%) were the most common presenting complaints among SARS-CoV-2 positive patients. Eighty (54%) SARS-CoV-2 positive patients reported prior contact with a positive case and 55 (40%) had bilateral infiltrates on CXR. Compared to SARS-CoV-2 negative patients, SARS-CoV-2 positive patients were more likely to identify cough, anosmia or dysgeusia, sore throat, fever, fatigue, myalgia or diarrhoea among their presenting symptoms. They were also more likely to reside in a residential aged care facility, identify as a healthcare worker, have a diagnosis of diabetes or be a non-smoker. In terms of examination findings, SARS-CoV-2 positive patients were more likely to have a fever (temperature ≥38°C) or hypoxia (oxygen saturation <92%). On investigation, SARS-CoV-2 positive patients were less likely to have a leucocytosis, more likely to have a thrombocytopaenia and more likely to have bilateral infiltrates on first CXR than SARS-CoV-2 negative patients.

For those variables which demonstrated a univariable association with the SARS-CoV-2 test result, Table 4 also provides the corresponding positive and negative likelihood ratios and summarises the parameters of a parsimonious clinical prediction model. Variables with a positive likelihood ratio of relatively large magnitude included contact with a confirmed SARS-CoV-2 positive case; a positive SARS-CoV-2 PCR swab in the previous 14 days; and anosmia or dysgeusia as a presenting complaint. The final set of four clinical variables (applying the "rule of thumb" outlined in the methods section) in the clinical prediction model for having a positive SARS-CoV-2 test result included self-reported fever, sore throat, bilateral infiltrates on CXR and absence of leucocytosis.

TABLE 3. *Outcomes by result of ED SARS-CoV-2 test*

Variable	SARS-CoV-2 test positive (*n* = 255)	SARS-CoV-2 test negative (*n* = 6264)	OR (95% CI)	*P*-value
Invasive mechanical ventilation in ED, *n* (%)				
Yes	5 (2)	88 (1)	1.4 (0.6–3.5)	0.47
Disposition destination from ED, *n* (%)				
Home	52 (20)	2525 (40)	Reference group	
Died in ED	3 (1)	8 (0)	18.2 (4.7–70.6)	<0.001
ICU	15 (6)	146 (2)	5.0 (2.7–9.1)	<0.001
OT	1 (0)	47 (1)	1.0 (0.1–7.6)	0.98
Ward (not ICU)	142 (56)	2453 (39)	2.8 (2.0–3.9)	<0.001
ED short stay unit	38 (15)	746 (12)	2.5 (1.6–3.8)	<0.001
Transfer to other hospital	3 (1)	238 (4)	0.6 (0.2–2.0)	0.41
DAMA	1 (0)	68 (1)	0.7 (1.0–5.2)	0.74
Other	0 (0)	33 (1)	—	—
Invasive mechanical ventilation in hospital, *n* (%)				
Yes	13 (5)	122 (2)	2.7 (1.5–4.9)	0.001
Discharge destination from hospital, *n* (%)				
Home	185 (73)	5082 (81)	Reference group	
Died in hospital	19 (7)	212 (3)	2.5 (1.5–4.0)	<0.001
Residential care facility	21 (8)	289 (5)	2.0 (1.3–3.2)	<0.001
Transfer to other hospital	22 (9)	457 (7)	1.3 (0.8–2.1)	0.23
DAMA	1 (0)	141 (2)	0.2 (0.0–1.4)	0.10
Hospital in the home	1 (0)	29 (0)	0.9 (0.1–7.0)	0.96
Other (includes current inpatients)	5 (2)	52 (1)	2.6 (1.0–6.7)	0.04

–, category omitted from estimation because of perfect prediction (empty cell); CI, confidence interval; DAMA, discharge against medical advice; ICU, intensive care unit; OR, odds ratio; OT, operating theatre.

Discussion

The present study, undertaken during Australia's 'second wave', is the largest analysis to date of patients with suspected and confirmed COVID-19 in Australian EDs. Although there was substantial variation in testing rates between sites, the overall burden of 'suspected COVID-19' was considerable. Only a small proportion returned a positive result.

A primary finding of the present study is a difference in the rates of mechanical ventilation and death between SARS-CoV-2 positive and SARS-CoV-2 negative patients. Specifically, SARS-CoV-2 positive patients were more likely to receive mechanical ventilation and more likely to die, both in the ED and during their hospital admission. Although the rates of mechanical ventilation and death were relatively low in both groups, especially when compared to data from overseas settings,[26,27] the present study demonstrates that ED patients diagnosed with COVID-19 have worse outcomes than comparable patients who return a negative SARS-CoV-2 test result.

COVED-4 is a cumulative analysis, incorporating data from the smaller set of sites and shorter time period reported in COVED-3.[2] With a five-fold increase in the number of COVID-19 patients subjected to analysis, across a broader selection of Australian EDs, the conservative conclusions of COVED-3, supporting a null effect of SARS-CoV-2 status on the outcomes of mechanical ventilation and in-hospital death, have been superseded. The difference may also reflect changes in testing criteria and admission thresholds over the 2-month period, in addition to, among those testing positive for SARS-CoV-2 in the ED, an increasing age and an increasing representation of residential age care facilities as the source of the ED referral.

The epidemiological and clinical predictors of a positive SARS-CoV-2 test identified in the present study are generally consistent with the findings of COVED-3.[2] Not surprisingly, contact with a confirmed case and a recent positive SARS-CoV-2 test are very strong risk factors for a diagnosis of COVID-19. Presenting from a

TABLE 4. *Results of analysis to determine univariable association and predictive performance of variables with being SARS-CoV-2 positive among patients tested for SARS-CoV-2 in the ED*

Variable	Missing >20% (yes/no)	Subgroups	SARS-CoV-2 test positive† (n = 162)	SARS-CoV-2 test negative (n = 2514)	OR (95% CI), P-value	Positive likelihood ratio	Negative likelihood ratio	Parsimonious model, OR (95% CI), P-value‡
Presenting complaint, n (%)								
Shortness of breath§	No	Yes	79 (51)	1025 (48)	1.1 (0.8–1.6), 0.48	—	—	—
Cough§	No	Yes	92 (61)	705 (34)	3.0 (2.2–4.2), <0.001	1.8	0.6	—
Anosmia or dysgeusia§	Yes	Yes	20 (19)	43 (3)	8.9 (5.0–15.8), <0.001	7.4	0.8	—
Sore throat§	Yes	Yes	37 (30)	419 (21)	1.6 (1.1–2.4), 0.03	1.4	0.9	2.7 (1.3–5.6), 0.005
Runny nose§	Yes	Yes	30 (25)	444 (23)	1.1 (0.7–1.7), 0.58	—	—	—
Fever§	No	Yes	83 (55)	645 (31)	2.8 (2.0–3.9), <0.001	1.8	0.6	2.6 (1.4–4.9), 0.002
Fatigue§	Yes	Yes	71 (58)	479 (27)	3.7 (2.5–5.3), <0.001	2.1	0.6	—
Myalgia§	Yes	Yes	42 (35)	245 (14)	3.4 (2.3–5.0), <0.001	2.5	0.8	—
Diarrhoea§	Yes	Yes	22 (18)	183 (10)	2.0 (1.2–3.2), <0.001	—	—	—
Number of days since first symptom, median (IQR)	Yes	NA	3 (1,7)	2 (1,5)	<0.001	—	—	—
Other relevant history, n (%)								
Overseas§ in previous 28 days	Yes	Yes	0 (0)	1 (0)	—	—	—	—
Contact with a confirmed case§	Yes	Yes	80 (54)	56 (3)	36.6 (24.0–55.6), <0.001	17.3	0.5	—
Residential aged care facility§	No	Yes	43 (27)	258 (13)	2.5 (1.8–3.7), <0.001	2.1	0.8	—
Health care worker§	Yes	Yes	12 (8)	80 (4)	1.9 (1.0–3.6), 0.04	1.9	1.0	—
Previous SARS-CoV-2 swab (within 14 days prior to ED presentation)	No	SARS-CoV-2 negative	12 (8)	231 (9)	Reference	—	—	·
		SARS-CoV-2 positive	39 (38)	15 (1)	50.1 (21.8–114.9), <0.001	62.7	0.6	—
		Swab result unknown	3 (3)	47 (2)	1.2 (0.3–4.5), 0.76	—	—	—
		No prior swab	50 (48)	2213 (88)	0.4 (0.2–0.8), 0.11	—	—	—

(Continues)

TABLE 4. *Continued*

Variable	Missing >20% (yes/no)	Subgroups	SARS-CoV-2 test positive† (n = 162)	SARS-CoV-2 test negative (n = 2514)	OR (95% CI), P-value	Positive likelihood ratio	Negative likelihood ratio	Parsimonious model, OR (95% CI), P-value‡
Comorbidities, n (%)								
Chronic respiratory	Yes	Yes	39 (25)	565 (29)	0.8 (0.6–1.2), 0.37	—	—	—
Obesity	Yes	Yes	18 (13)	293 (17)	0.7 (0.4–1.2), 0.17	—	—	—
Smoker	Yes	Yes	26 (20)	736 (40)	0.4 (0.2–0.6), <0.001	0.5	1.3	—
Chronic cardiac	No	Yes	35 (23)	540 (27)	0.8 (0.5–1.2), 0.23	—	—	—
Hypertension	No	Yes	53 (34)	710 (36)	0.9 (0.7–1.3), 0.69	—	—	—
Diabetes mellitus	Yes	Yes	43 (28)	326 (17)	1.9 (1.3–2.8), <0.001	1.7	0.9	—
Malignant neoplasm	Yes	Yes	7 (5)	182 (9)	0.5 (0.2–1.0), 0.05	—	—	—
Immunosuppressive pharmacotherapy	Yes	Yes	10 (7)	203 (11)	0.6 (0.3–1.1), 0.12	—	—	—
Examination – first vital signs in ED								
Temperature§ (°C), mean (SD)	No	NA	37.0 (0.9)	36.6 (0.8)	2.5 (2.0–3.0), <0.001	—	—	—
Fever recorded§ (temperature ≥38°C), n (%)	Yes	Yes	26 (16)	82 (3)	5.5 (3.4–8.9), <0.001	4.8	0.9	—
SaO$_2$ (%), mean (SD)	No	NA	96 (4)	97 (3)	0.9 (0.9–0.9), <0.001	-	-	—
Hypoxia (SaO$_2$ <92%), n (%)	Yes	Yes	16 (11)	88 (4)	3.2 (1.8–5.6), <0.001	1.5	0.8	—
Systolic blood pressure (mmHg), mean (SD)	No	NA	132 (25)	138 (27)	1.0 (1.0–1.0), 0.005	—	—	—
Hypotension (SBP <100 mmHg), n (%)	Yes	Yes	10 (6)	108 (4)	1.5 (0.7–2.8), 0.27	—	—	—
Examination – other								
Abnormality on chest auscultation¶, n (%)	Yes	Yes	54 (41)	77 (59)	1.9 (1.3–2.8), <0.001	—	—	—
Investigations – imaging¶								

TABLE 4. *Continued*

Variable	Missing >20% (yes/no)	Subgroups	SARS-CoV-2 test positive† (n = 162)	SARS-CoV-2 test negative (n = 2514)	OR (95% CI), *P*-value	Positive likelihood ratio	Negative likelihood ratio	Parsimonious model, OR (95% CI), *P*-value‡
CXR report, *n* (%)	Yes	No	48 (35)	1022 (63)	Reference	—	—	-
		Yes – bilateral infiltrates	55 (40)	76 (5)	15.4 (9.8–24.2), <0.001	8.6	0.6	15.3 (7.4–31.5), <0.001
		Yes – other abnormality	33 (24)	513 (32)	1.4 (0.9–2.2), 0.18	—	—	—
Investigations – blood tests¶								
WCC (×10^9/L), mean (SD)	No	NA	6 (3)	10 (7)	0.8 (0.7–0.8), <0.001	—	—	—
Leucocytosis (WCC >11.0 [×10^9/L]), *n* (%)	Yes	Yes	11 (7)	661 (29)	0.2 (0.1–0.4), <0.001	0.3	1.3	0.3 (0.1–0.7), 0.005
Platelet count (×10^9/L), mean (SD)	No	NA	227 (103)	243 (92)	1.0 (1.0–1.0), 0.03	—	—	—
Thrombocytopaenia (platelet count <150 × 10^9/L), *n* (%)	Yes	Yes	29 (19)	272 (12)	1.8 (1.1–2.7), 0.01	1.6	0.9	—
						AIC		347
						AUROC		0.80 (0.74–0.85)

†SARS-CoV-2 positive cases are defined in this COVED report as having a SARS-CoV-2 test during their ED presentation for which the result is positive for SARS-CoV-2. ‡Clinical variables with a statistically significant univariable association with a SARS-CoV-2 positive test in ED (i.e. excluding patients with a positive SARS-CoV-2 test in the previous 14 days or contact with a person confirmed as SARS-CoV-2 positive). §One of the criteria for testing (i.e. inclusion in the present study). ¶May not have been performed. –, not meeting criteria for calculation of likelihood ratios (no statistically significant association with SARS-CoV-2 test result) and/or not included in final parsimonious prediction model; AIC, Akaike information criteria; AUROC, area under the receiver operating characteristic curve; CI, confidence interval; IQR, interquartile range; NA, not applicable; OR, odds ratio; SBP, systolic blood pressure; WCC, white blood cell count.

residential aged care facility, or being a healthcare worker, were also confirmed as predictive in the present study. Anosmia remained a strong determinant of SARS-CoV-2 positivity, as did the independent presence of subjective fever, bilateral infiltrates on CXR or the absence of a leucocytosis.

These results are also broadly consistent with the findings of overseas analyses, particularly in relation to the frequency of fever and the predictive value of hyposmia and hypogeusia.[9] While few studies have been undertaken specifically in the emergency care context, a recent model derived from ED patients has identified a history of exposure, elevated temperature, reduced white cell count and positive CXR as the strongest predictors of a COVID-19 diagnosis.[14] However, the present study also demonstrated that the absence of these variables did not exclude COVID-19 and should not be used as negative predictive tools.

Globally, several attempts have been made to use data of this nature to derive and validate severity prediction tools. These include the 4C mortality score, based on ISARIC data, and the QCOVID living risk prediction algorithm.[13,28] The relatively low number of COVID-19 cases in the COVED registry prohibits this type of analysis, but it may be possible to use the dataset to externally validate these approaches.

Consistent with previous observations, the burden of suspected COVID-19 cases was high and is likely to contribute to crowding and prolonged length of stay in the ED.[2,6,29] This has the potential to exacerbate access block and delay definitive care. Prolonged test turnaround times contribute to this burden because patients spend a longer period of time in isolation while awaiting test results. The potential for more widespread access to accurate rapid testing may mitigate this issue.

There are several limitations to the present study. First, data on SARS-CoV-2 negative patients were not available for all sites (Table 1), limiting the generalisability of the inferential analyses to the EDs that provided complete data. Second, there was a significant amount of missing clinical data. As summarised in Table 4, some variables were missing up to 30% of observations. This reflects the challenges of systematic, prospective data collection in the dynamic environment of the ED. Third, the study used the results of PCR swab tests, ordered during the ED encounter, as the criterion for SARS-CoV-2 positivity. The sensitivity for this test, at least when conducted once, is estimated to be 70–80%.[9,30] A fourth limitation was that the study's inclusion criteria were defined, from the commencement of the COVED Project on 1 April 2020, as being tested for SARS-CoV-2 in the ED. As the second wave evolved, according to individual site-level policies, a proportion of patients with confirmed COVID-19 who were diagnosed in the community were not re-tested on arrival in the ED. The magnitude of this variation in practise has not been established. Finally, while more a caution than a limitation, it is important to emphasise that the data used in the COVED-3 analysis (eight EDs across July 2020) has been incorporated, as part of a planned series of reports, into this larger, cumulative analysis (12 EDs across July and August 2020). These two reports are not independent of each other, but rather an intended progressive analysis on an expanding dataset, whereby the findings from the analysis of the larger dataset ought to be regarded as providing more precision and generalisability than the previous analysis of the then-available data.

Conclusion

Despite Australia's relative success in containing COVID-19, a substantial proportion of patients presenting to Australian EDs in July and August 2020 underwent SARS-CoV-2 testing and required isolation. Only a small proportion was diagnosed with COVID-19, with self-reported fever, sore throat, bilateral infiltrates on CXR and absence of leucocytosis being strong predictors. In this sample, the presence of SARS-CoV-2 on naso-pharyngeal testing was associated with mechanical ventilation and death in hospital.

Author contributions

All authors have contributed to the concept and design of this Original Research, including its analysis plan, and have critically reviewed the Original Research for content.

Competing interests

GMOR, BM, VT, JSF and PAC are section editors for *Emergency Medicine Australasia*.

Data availability statement

Data that support the findings of this study may be available upon reasonable request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

1. COVID-19 National Incident Room Surveillance Team. COVID-19 Australia: epidemiology report 30: fortnightly reporting period ending 22 November 2020. *Commun. Dis. Intell.* 2020; https://doi.org/10.33321/cdi.2020.44.91.

2. O'Reilly GM, Mitchell RD, Mitra B *et al*. Epidemiology and clinical features of emergency department patients with suspected and confirmed COVID-19: a multisite report from the COVID-19 Emergency Department Quality Improvement Project for July 2020 (COVED-3). *Emerg. Med. Australas.* 2020; https://doi.org/10.1111/1742-6723.13651.

3. Staib A, Small N. Emergency medicine's COVID future: facing the triple challenge after flattening the curve. *Emerg. Med. Australas.* 2020; 32: 880–2.

4. Kam AW, Chaudhry SG, Gunasekaran N, White AJR, Vukasovic M, Fung AT. Fewer presentations to metropolitan emergency departments during the COVID-19 pandemic. *Med. J. Aust.* 2020; 213: 370–1.

5. Mitchell RD, O'Reilly GM, Mitra B, Smit DV, Miller J, Cameron PA. Impact of COVID-19 state of emergency restrictions on presentations to two Victorian emergency departments. *Emerg. Med. Australas.* 2020; 32: 1027–33.

6. Mazurik L, Javidan A, Higginson I *et al*. Early lessons from COVID-19 that may reduce future emergency department crowding. *Emerg. Med. Australas.* 2020; 32: 1077–9.

7. Australasian College for Emergency Medicine. *ED Crowding is Unethical in a COVID-19 World.* [Cited 1 Jul 2020.] Available from URL: https://acem.org.au/News/June-2020/ED-crowding-is-unethical-in-a-COVID-19-world

8. Sperrin M, McMillan B. Prediction models for covid-19 outcomes. *BMJ* 2020; 371: m3777.

9. Carpenter CR, Mudd PA, West CP, Wilber E, Wilber ST. Diagnosing COVID-19 in the emergency department: a scoping review of clinical examinations, laboratory tests, imaging accuracy, and biases. *Acad. Emerg. Med.* 2020; 27: 653–70.

10. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E *et al*. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. *Travel Med. Infect. Dis.* 2020; 34: 101623.

11. Ferreira-Santos D, Maranhão P, Monteiro-Soares M. Identifying common baseline clinical features of COVID-19: a scoping review. *BMJ Open* 2020; 10: e041079.

12. Vetter P, Vu DL, L'Huillier AG, Schibler M, Kaiser L, Jacquerioz F. Clinical features of covid-19. *BMJ* 2020; 369: m1470.

13. Knight SR, Ho A, Pius R *et al*. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. *BMJ* 2020; 370: m3339.

14. McDonald SA, Medford RJ, Basit MA, Diercks DB, Courtney DM. Derivation with internal validation of a multivariable predictive model to predict COVID-19 test results in emergency department patients. *Acad. Emerg. Med.* 2020; 7: acem.14182.

15. Wynants L, Van Calster B, Collins GS *et al*. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. *BMJ* 2020; 369: m1328.

16. O'Reilly GM, Mitchell RD, Noonan MP *et al*. Informing emergency care for COVID-19 patients: the COVID-19 emergency department quality improvement project protocol. *Emerg. Med. Australas.* 2020; 32: 511–4.

17. O'Reilly GM, Mitchell RD, Rajiv P *et al*. Epidemiology and clinical features of emergency department patients with suspected COVID-19: initial results from the COVID-19 Emergency Department Quality Improvement Project (COVED). *Emerg. Med. Australas.* 2020; 32: 638–45.

18. O'Reilly G, Mitchell R, Wu J *et al*. Epidemiology and clinical features of emergency department patients with suspected COVID-19: results from the first month of the COVED quality improvement project (COVED-2). *Emerg. Med. Australas.* 2020; 32: 814–22.

19. Department of Health and Human Services. *Assessment and Testing Criteria for Coronavirus (COVID-19).* [Cited 1 Aug 2020.] Available from URL: https://www.dhhs.vic.gov.au/assessment-and-testing-criteria-coronavirus-covid-19

20. Tasmanian Government. *Testing for COVID-19.* [Cited 1 Sep 2020.] Available from URL: https://coronavirus.tas.gov.au/keeping-yourself-safe/testing-for-covid19

21. NSW Health. *Updated Advice on Testing.* [Cited 4 Aug 2020.] Available from URL: https://www.health.nsw.gov.au/Infectious/covid-19/Pages/case-definition.aspx

22. Queensland Health. *COVID-19 Information for Queensland Clinicians.* [Cited 1 Dec 2020.] Available from URL: https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/novel-coronavirus-qld-clinicians/public-health-alerts

23. International Severe Acute Respiratory and Emerging Infection Consortium. *COVID-19 Clinical Research Resources.* [Cited 29 Mar 2020.] Available from URL: https://isaric.tghn.org/covid-19-clinical-research-resources/

24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG.

Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. *J. Biomed. Inf.* 2009; **42**: 377–81.

25. Harris PA, Taylor R, Minor BL *et al.* The REDCap consortium: building an international community of software platform partners. *J. Biomed. Inform.* 2019; **95**: 103208.

26. Wunsch H. Mechanical ventilation in COVID-19: interpreting the current epidemiology. *Am. J. Respir. Crit. Care Med.* 2020; **202**: 1–4.

27. Burrell AJC, Pellegrini B, Salimi F *et al.* Outcomes for patients with COVID-19 admitted to Australian intensive care units during the first four months of the pandemic. *Med. J. Aust.* 2020; https://doi.org/10.5694/mja2.50883.

28. Clift AK, Coupland CAC, Keogh RH *et al.* Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. *BMJ* 2020; **371**: m3731.

29. O'Reilly G, Mitchell R, Mitra B *et al.* The impact of patient isolation on emergency department length of stay: a retrospective cohort study using the Registry for Emergency Care (REC-1). *Emerg. Med. Australas.* 2020; **32**: 1034–9.

30. Woloshin S, Patel N, Kesselheim A. False negative tests for SARS-CoV-2 infection – challenges and implications. *N. Engl. J. Med.* 2020; **38**: 1–3.